

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent of:

BACHMANN *et al.*

Patent. No.: 7,279,165 B2

Issued: October 9, 2007

For: **Amyloid β 1-6 Antigen Arrays**

Confirmation No.: 5998

Art Unit: 1648

Examiner: Horning, Michelle S.

Atty. Docket: 1700.0350002/BJD/GAL

**Request Under 37 C.F.R. § 3.81(b) For Correction of Patent to
State the Name of An Assignee**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Attn: Mail Stop PETITIONS

Sir:

It is hereby requested under 37 C.F.R. § 3.81(b) that the above-captioned United States Patent be corrected to state the name of co-assignee Novartis Pharma AG, which would be in addition to the name of co-assignee Cytos Biotechnology AG (whose name is included in the Assignee information shown on the face page of the issued patent). The assignment to Novartis Pharma AG was recorded in the Assignment records of the USPTO on January 23, 2004, beginning at Reel No. 014280, Frame No. 0677; a copy of the Notice of Recordation reflecting the recordation of this Assignment is appended hereto.

Thus, the application that resulted in the issuance of the captioned patent was assigned to both Cytos Biotechnology AG and Novartis Pharma AG during the pendency of the application. Patentees note, however, that the Form PTOL-85B that was submitted with payment of the Issue Fee in the captioned matter on April 25, 2007, listed only Cytos Biotechnology AG as the assignee and erroneously did not list Novartis

Pharma AG as an assignee. Patentees hereby state that this error was inadvertent and occurred without deceptive intent.

In accordance with the decision on Request for Certificate of Correction mailed July 21, 2008, Patentees thus respectfully request that the Assignee of the captioned patent be corrected under 37 C.F.R. §3.81(b) to properly add Novartis Pharma AG as an assignee, such that both Cytos Biotechnology AG and Novartis Pharma AG are of record as assignees of the captioned patent. Patentees also respectfully request that the file of the captioned patent be forwarded to the Certificates of Correction Branch of the USPTO for issuance of a Certificate of Correction in this matter, to reflect the addition to the captioned patent of Novartis Pharma AG as an assignee thereof. It is respectfully believed that issuance of a Certificate of Correction to add Novartis Pharma AG as an assignee is proper, as the assignment was recorded prior to issuance of the patent.

Remarks

The above-noted correction does not involve such changes in the patent as would constitute new matter or would require reexamination.

This request is accompanied by payment of the \$130.00 fee set forth in 37 CFR § 1.117(h), as well as payment of the \$100.00 fee for issuance of a Certificate of Correction under 37 CFR § 1.323. Fee payment is provided via online credit card payment through EFS-Web. The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Prompt and favorable consideration of this Request, correction of the Assignee, and issuance of a Certificate of Correction reflecting this correction of the Assignee, are respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono

Attorney for Patentee Cytos Biotechnology AG
Registration No. 42,473

Date: July 28, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
853543_1.DOC



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231



800009944A

JANUARY 23, 2004

PTAS
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20005

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/23/2004

REEL/FRAME: 014280/0677
NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

ORTMANN, RAINER

DOC DATE: 01/06/2004

ASSIGNOR:

LUOND, RAINER

DOC DATE: 12/12/2003

ASSIGNOR:

STAUFENBIEL, MATTHIAS

DOC DATE: 12/15/2003

ASSIGNOR:

FREY, PETER

DOC DATE: 12/12/2003

ASSIGNEE:

NOVARTIS PHARMA AG
LICHTSTRASSE 35
BASEL, SWITZERLAND CH-4002

014280/0677 PAGE 2

SERIAL NUMBER: 10622087
PATENT NUMBER:

FILING DATE: 07/18/2003
ISSUE DATE:

SHAREILL COLES, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS